A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC)Xingsheng Hu, Yan Sun, Shun Chang Jiao et al.|Lung Cancer|2014Cited by 51
IL13Rα2-targeted third-generation CAR-T cells with CD28 transmembrane domain mediate the best anti-glioblastoma efficacyAiqin Gu, Xiaosong Zhong|Cancer Immunology Immunotherapy|2023Cited by 16
Safety and efficacy results of a phase IV, open-label, multicenter, safety-monitoring study of icotinib in treating advanced non-small cell lung cancer (NSCLC): ISAFE study.Fenlai Tan, Yan Sun, Aiqin Gu et al.|Journal of Clinical Oncology|2013Cited by 5